Next generation MRD.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. A multigene array for measurable residual disease detection in AML patients undergoing SCT.Bone marrow transplantation · 2015
   Trial
2. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.Blood advances · 2021
   Article
3. Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.Seminars in hematology · 2015
   Review

Corrections and comments

• Comment on
  Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.2014

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as